The Efficacy of Vitamin D Supplementation for Migraine: A Meta-Analysis of Randomized Controlled Studies
Clin Neuropharmacol. 2021 Jan-Feb 01;44(1):5-8. doi: 10.1097/WNF.0000000000000419.
Yuan-Feng Zhang 1, Zhi-Qiang Xu, Hong-Jie Zhou, Ya-Zhen Liu, Xiao-Jiang Jiang
Headache has the following on metals and migraines
Compared blood levels of 25 people with migraines to 25 people without GreenMedInfo
| Metal | Migraine | No Migraine | Migraine Ratio |
| Cadmium | 0.36 ug | 0.09 ug | 4X MORE if increase |
| Iron | 0.97 ug | 0.48 ug | 2X MORE if increase |
| Lead | 1.48 ug | 0.78 ug | 2X MORE if increase |
| Magnesium* | 10.6 ug | 34.5 ug | 3.5X LESS if increase |
| Zinc* | 0.24 ug | 5.77 ug | 24X LESS if increase |
- Note: Both Zinc and Magnesium increase the activation of the Vitamin D Receptor, which allows more vitamin D into cells
Also
- Cluster Headaches treated by high-dose Vitamin D, etc. (interview and transcript) - Feb 2022 Zinc is mentioned
- Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial - Sept 2020 No such attachment on this page
- Zinc somewhat reduced Migraine in RCT - Sept 2020
Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial https://doi.org/10.1186/s12937-020-00618-9 FREE PDF
Introduction: The efficacy of vitamin D for migraine remains controversial. We conduct a systematic review and meta-analysis to explore the influence of vitamin D versus placebo on treatment in migraine patients.
Methods: We search PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through April 2020 for randomized controlled trials assessing the effect of vitamin D versus placebo on treatment efficacy in migraine patients. This meta-analysis is performed using the random-effect model.
Results: Five randomized controlled trials are included in the meta-analysis. Overall, compared with control group in migraine patients, vitamin D treatment is associated with
- substantially reduced number of headache days
- (standard mean difference [SMD], -0.53; 95% confidence interval [CI], -0.83 to -0.23; P = 0.0006),
- frequency of headache attacks (SMD, -1.09; 95% CI, -1.86 to -0.32; P = 0.006),
- headache severity (SMD, -0.55; 95% CI, -0.91 to -0.19; P = 0.0003), and
- Migraine Disability Assessment score (SMD, -0.76; 95% CI, -1.11 to -0.40; P < 0.0001).
Conclusions: Vitamin D treatment is effective to alleviate migraine.
References
- Ghorbani Z, Togha M, Rafiee P, et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurol Sci 2019;40(12):2459–2477.
- MacGregor EA. Migraine. Ann Intern Med 2017;166(7):ITC49–ITC64.
- Schwedt TJ. Chronic migraine. BMJ 2014;348:g1416.
- Dodick DW, Silberstein SD, Lipton RB, et al. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data. Cephalalgia 2019;39:945–956. 333102418825382.
- Mattle HP, Nedeltchev K, Schankin C, et al. Migraine Headache: Clinical Association With PFO and Observational Studies, Patent Foramen Ovale Closure for Stroke, Myocardial Infarction, Peripheral Embolism, Migraine, and Hypoxemia. Elsevier; 2020:117–127.